A review of terms used to define cutaneous squamous cell carcinoma with a poor prognosis
Actas Dermosifiliogr (Engl Ed). 2020 May;111(4):281-290.
doi: 10.1016/j.ad.2019.06.005.
Epub 2020 Apr 28.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca, España; Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, España. Electronic address: [email protected].
- 2 Departamento de Dermatología, Instituto Dermatológico GlobalDerm, Palma del Río, Córdoba, España.
- 3 Servicio de Dermatología, Clínica Universitaria de Navarra, Pamplona, Navarra, España.
- 4 Servicio de Dermatología, Hospital Universitario La Fe, Facultad de Medicina, Universidad de Valencia, Valencia, España.
- 5 Servicio de Dermatología, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBER de Enfermedades Raras, Barcelona, España.
- 6 Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España.
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in humans and its incidence is both underestimated and on the rise. cSCC is referred to in the literature as high-risk cSCC, locally advanced cSCC, metastatic cSCC, advanced cSCC, and aggressive cSCC. These terms can give rise to confusion and are not always well defined. In this review, we aim to clarify the concepts underlying these terms with a view to standardizing the description of this tumor, something we believe is necessary in light of the new drugs that have been approved or are in development for cSCC.
Keywords:
Carcinoma epidermoide cutáneo; Carcinoma epidermoide cutáneo de alto riesgo; Carcinoma escamoso cutáneo; Cutaneous squamous cell carcinoma; Estadificación; High-risk cutaneous squamous cell carcinoma; Staging.
Copyright © 2020 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Carcinoma, Squamous Cell* / diagnosis
-
Humans
-
Neoplasm Staging
-
Skin Neoplasms* / diagnosis